XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
| Three Months Ended September 30,
| 2025 |  | 2024 |  |
Revenue from collaborative arrangement | $ | — |  |  | $ | — |  |  |
Less: |  |  |  |  |
Research and development: |  |  |  |  |
INO-3107 | 3,352,458 |  |  | 7,009,169 |  |  |
INO-3112 and other Immuno-oncology | 1,574,238 |  |  | 1,726,382 |  |  |
Other programs (a) | 96,971 |  |  | (1,119,600) |  |  |
Engineering and device-related | 4,323,775 |  |  | 5,602,688 |  |  |
Stock-based compensation | 302,249 |  |  | 590,211 |  |  |
Other unallocated expenses | 3,683,638 |  |  | 4,924,734 |  |  |
General and administrative | 7,877,126 |  |  | 8,613,895 |  |  |
Total operating expenses | 21,210,455 |  |  | 27,347,479 |  |  |
Interest income | 552,108 |  |  | 1,106,758 |  |  |
Change in fair value of common stock warrant liabilities | (22,515,730) |  |  | — |  |  |
(Loss) gain on investment in affiliated entity | (589,618) |  |  | 324,251 |  |  |
Net unrealized gain on available-for-sale equity securities | 205,259 |  |  | 1,330,811 |  |  |
Other expense, net | (1,938,236) |  |  | (579,819) |  |  |
Net loss | $ | (45,496,672) |  |  | $ | (25,165,478) |  |  |
| Nine Months Ended September 30,
| 2025 |  | 2024 |  |
Revenue from collaborative arrangement | $ | 65,343 |  |  | $ | 100,762 |  |  |
Less: |  |  |  |  |
Research and development: |  |  |  |  |
INO-3107 | 10,790,120 |  |  | 25,697,828 |  |  |
INO-3112 and other Immuno-oncology | 4,327,081 |  |  | 5,309,964 |  |  |
Other programs (a) | 357,884 |  |  | (292,372) |  |  |
Engineering and device-related | 14,470,247 |  |  | 14,192,615 |  |  |
Stock-based compensation | 1,177,331 |  |  | 2,240,800 |  |  |
Other unallocated expenses | 12,822,975 |  |  | 15,586,056 |  |  |
General and administrative | 25,465,208 |  |  | 29,395,232 |  |  |
Total operating expenses | 69,410,846 |  |  | 92,130,123 |  |  |
Interest income | 1,970,823 |  |  | 3,914,406 |  |  |
Interest expense | — |  |  | (177,833) |  |  |
Change in fair value of common stock warrant liabilities | (20,680,868) |  |  | — |  |  |
Gain (loss) on investment in affiliated entity | 881,886 |  |  | (136,061) |  |  |
Net unrealized gain on available-for-sale equity securities | 1,104,782 |  |  | 1,810,868 |  |  |
Other expense, net | (2,641,901) |  |  | (1,254,466) |  |  |
Net loss | $ | (88,710,781) |  |  | $ | (87,872,447) |  |  |
(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration